digital cash system Related searches

Spot silver fell more than 1.00% in the day and is now reported at $30.63 per ounce.Xinxiangwei: Shareholder Xinyu Yijiade intends to reduce its shareholding by no more than 1%. Xinxiangwei announced that as of the disclosure date, Shareholder Xinyu Yijiade holds 20,175,800 shares of the company, accounting for 4.39% of the company's total share capital. Xinyu Yijiade plans to reduce the number of shares of the company by no more than 4,595,300 shares through centralized bidding or block trading of Shanghai Stock Exchange within 90 days after 15 trading days from the date of announcement, and the proportion of reduced shares in the company's total share capital is no more than 1%.Navigation warning to carry out military missions in the northern Bohai Sea. According to the website of China Maritime Safety Administration, Huludao Maritime Safety Administration issued a navigation warning. From 6: 00 to 16: 00 on December 14, military exercises were held in parts of the northern Bohai Sea, and it was forbidden to enter.

Market News: Turkish anti-monopoly agency fined Google $75 million for advertising technology investigation.Nearly 30 listed companies announced after-hours that their products would be selected, and the tenth batch of centralized drug procurement (centralized drug procurement) organized by the state was opened in Shanghai yesterday. According to incomplete statistics, as of press time, it includes Fuyuan Pharmaceutical, Yifan Pharmaceutical, ST Tiansheng, Hokuriku Pharmaceutical, Haizheng Pharmaceutical, Zhongheng Group, Yuandong Bio, Kelun Pharmaceutical, China Resources Shuanghe, Sinopharm Modern, Lingkang Pharmaceutical, Xuantai Pharmaceutical, Jiuzhou Pharmaceutical, Kang Enbei, Laimei Pharmaceutical, Kanghong Pharmaceutical, Huasen Pharmaceutical, Borui Pharmaceutical, Xianzeng Pharmaceutical. Among them, Kelun Pharmaceutical announced that 12 kinds of drugs, such as sodium acetate Ringer injection, sodium bicarbonate Ringer injection and gliclazide tablets, were to be selected.Market News: Director of South Korea's National Police Agency will be arrested.

Market News: Turkish anti-monopoly agency fined Google $75 million for advertising technology investigation.Luo Zhaohui, Director General of the United Nations Office, should meet with Egyptian Minister of Foreign Affairs and Immigration Abdul Ati by appointment. On December 13th, Luo Zhaohui, Director General of China International Development Cooperation Agency, should meet with Egyptian Minister of Foreign Affairs and Immigration Abdul Ati by appointment. Changshou Hailong, Director of Regional Division I, Li Ming, Director of International Cooperation Department, and Hanafi, Egyptian Ambassador to China, attended the meeting. Luo said that this year marks the 10th anniversary of the "China-Egypt Partnership Year" and the establishment of a comprehensive strategic partnership between the two countries. Under the strategic guidance of the leaders of the two countries, bilateral relations have achieved great-leap-forward development and achieved fruitful results. The General Office of the State Council is willing to work closely with the Egyptian Ministry of Foreign Affairs and the Ministry of International Affairs to implement the important consensus reached by the leaders of the two countries and the outcome of the Beijing Summit of the Forum on China-Africa Cooperation, deepen pragmatic cooperation in the development field between the two sides, and promote the common development of the global South. A thanked China for its long-term strong support for Egypt's economic and social development and improvement of people's livelihood, and expressed its willingness to work closely with China under the guidance of the consensus of the two heads of state to promote the joint construction of the Belt and Road Initiative and implement global development initiatives, continuously expand the breadth and depth of development cooperation between the two countries, and make new contributions to the development of comprehensive strategic partnership between the two countries.Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.